AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/10.31579/2768-0487/124
1 Department of Anesthesiology and Intensive Care, Faculty of Medicine, Gazi University, Ankara, Turkey.
2 Department of Pediatric Hematology and Director of Hemostasis and Hematology, Faculty of Medicine, Gazi University, Ankara, Turkey.
3 Department of Pediatric Hematology, Faculty of Medicine, Gazi University, Ankara, Turkey
4 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
5 Department of Pulmonary Critical Care Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey.
*Corresponding Author: Ümmügülsüm Gaygisiz, Department of Anesthesiology and Intensive Care, Faculty of Medicine, Gazi University, Ankara, Turkey.
Citation: Ümmügülsüm Gaygisiz, Zühre Kaya, Serap Kirkiz, Hasan Selçuk Özger, Müge Aydoğdu, et al, (2024), The Prognostic Value of Extended Inflammation Parameters and Soluble Fibrin Monomer Complex in Covid-19 Patients in The Intensive Care Unit, Journal of Clinical and Laboratory Research, 7(3); DOI:10.31579/2768-0487/124
Copyright: © 2024, Ümmügülsüm Gaygisiz. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 09 January 2024 | Accepted: 24 January 2024 | Published: 29 January 2024
Keywords: covid-19; extended inflammatory parameters; fibrin monomer; intensive care; mortality
Objective: This study aimed to investigate how extended inflammation markers (EIM) and soluble fibrin monomer complex (SFMC) affected the prognosis of COVID-19-infected patients in the intensive care unit (ICU).
Methods: In this study, 73 adults with COVID-19 were included. Patients were divided into two groups: those who died (Group 1; n = 45) and those who survived (Group 2; n = 28). SFMC and EIM [neutrophil reactivity index (NEUT-RI) and neutrophil granularity index (NEUT-GI), reactive lymphocyte (RE-LYMPH), antibodies synthesizing lymphocyte (AS-LYMP), neutrophil/lymphocyte ratio (NLR) and immature granulocyte/lymphocyte ratio (IGLR)], were analyzed in the first 28 days of these patients' follow-up.
Results: The median NLR during the first four weeks, IGLR in the first two weeks, RE-LYMPH in the first three weeks, NEUT-RI and NEUT-GI values in the second week, and AS-LYMP in the third week of follow-up were significantly higher in Group 1 than in Group 2 (p<0.05). The median D-Dimer level during the first three weeks and SFMC value in the first week of follow-up were significantly higher in Group 1 than in Group 2 (p<0.05). In patients with COVID-19, older age (≥65 years), nosocomial infection, blood product use, longer ICU stay (>7 days), high DIC (>5), and comorbidities (>3) scores were all risk factors for mortality. In ROC analysis, the cut-off values for NLR and SFMC to predict mortality were 6 and 6.5, respectively.
Conclusion: Our data show that elevated NLR and SFMC values in the first week should alert physicians to the risk of life-threatening COVID-19 complications.
Coronavirus disease 2019 (COVID-19) may cause a wide range of clinical symptoms, from asymptomatic infections to fatal disorders.1 In this SARS-CoV-2 viral infection, a mechanism known as immunothrombosis develops, in which the immune and coagulation systems collaborate to stop infections and limit their spread.1,2 Clinicians required quick, low-cost, and routine measures to predict the severity of the disease and demonstrate the dysregulated immune response during the pandemic period. C-reactive protein, ferritin, D-dimer, and lactate dehydrogenase are all easily measured parameters that are routinely used to predict severe disease and mortality.3-5 In recent years, extended inflammation markers (EIM) that can reveal the activation and functional status of the leukocyte series with the onset of an inflammatory stimulus (neutrophil reactivity and granularity index showing neutrophil activation, immature granulocytes (IG) indicating neutrophil precursors and antibody synthesizing lymphocytes) have been performed in parallel with technological developments.6 This information can be utilized to influence the severity of the immune response and the course of the disease in the early stages of infection.7,8 In addition to D-dimer, soluble fibrin monomer complex (SFMC) can be assessed in a coagulation device, which is considered an early indicator of thrombosis.9 SFMC is significantly elevated at the onset of thrombotic diseases such as myocardial infarction (MI) or deep vein thrombosis (DVT) and is a better indicator than fibrin degradation products (e.g., D-dimer) in revealing disseminated intravascular coagulation (DIC).10,11 Although there is no study in the literature that evaluated the EIM and SFMC together in determining the prognosis of COVID-19 patients, there are a few studies that evaluated the EIM and SFMC separately in terms of the effects on disease prognosis.12-17 We investigated how changes in EIM and SFMC levels predicted mortality in COVID-19 patients who needed intensive care unit (ICU) in our research.
The cross-sectional study examined COVID-19 patients at the ICU of Gazi University Faculty of Medicine Hospital between April 2020 and December 2021. The ethics committee of the Gazi Clinical Research Ethics Committee approved the study.
Study Population
Adult patients (>18 years old) with ICD U07.3 who were hospitalized in the ICU and tested positive for SARS-CoV-2 PCR in nasopharyngeal, oropharyngeal, or lower respiratory tract samples were included in the study. Patients infected with other viruses have been excluded.
Study Design
Patients were categorized into two groups based on their survival status: those who did not survive (Group 1; n = 45) and those who did survive (Group 2; n = 28). The hospital's record system was used to access detailed file information for each patient. Comorbidities (chronic heart failure, chronic lung disease, chronic renal disease, cancer, diabetes mellitus, etc.) were recorded for each patient, and the Charlson Comorbidity Index18 was calculated. During ICU monitoring, thromboembolic events (pulmonary thromboembolism, DVT, MI, acute stroke), clinically apparent DIC (bleeding or thrombosis), and nosocomial infections were documented. COVID-19 pneumonia severity and the need for ICU were recorded throughout the study, and treatments were planned following the Turkish Ministry of Health's COVID-19 Diagnosis and Treatment Guidelines.19 Blood products, Convalescent plasma, steroids, and tocilizumab were used.
Laboratory Parameters
Blood samples for complete blood count (CBC) parameters containing extended inflammation parameters, as well as coagulation tests including SFMC, were collected from these patients at the following time intervals: during the first week (0-7 days), second week (8-14 days), third week (15-21 days), and fourth week (22-28 days) following the initial diagnosis. The automated blood cell analyzer Sysmex XN® 1000 (Sysmex Corporation, Kobe, Japan) was used to assess routine CBC samples as well as the extended inflammatory parameters. Among these variables, neutrophil reactivity index (NEUT-RI), neutrophil granularity index (NEUT-GI), reactive lymphocytes (RE-LYMPH), and antibody-synthesizing lymphocytes (AS-LYMPH) were studied as research parameters beyond routine assessments. In addition, neutrophil-to-lymphocyte ratios (NLR) and immature granulocyte-to-lymphocyte ratios (IGLR) were calculated.
A coagulation device (Diagnostics Stago®, Asnières sur Seine, France) was used to perform tests on soluble fibrin monomer complex and D-dimer. All hemostatic parameters were used to calculate DIC scores based on ISTH.20,21 All recorded laboratory parameters are presented in Table 1.
The SPSS 22.0 statistical program (SPSS, Inc., Chicago, IL, USA) was used to analyze all data. Continuous variables with a normal distribution were given as mean and standard deviation (SD), while non-normal variables were reported as median and interquartile ranges (IQR). The categorical variables of the patients were recorded as counts and percentages, and they were compared using the chi-square test and the resulting Odds ratio (OR) and 95% confidence intervals (95% CI). Non-parametric data were evaluated using the Mann-Whitney U test, and parametric data were evaluated using the student t-test. To assess the predictive usefulness of EIM and SFMC in predicting mortality among COVID-19 patients, ROC curves were generated and the area under the curve (AUC) was calculated. A p-value of less than 0.05 was considered statistically significant.
During the follow-up period, 45 patients in Group 1 died (62%) while 28 patients in Group 2 survived (38%). Gender distribution did not differ statistically between the two groups (Table 1).
| Nonsurvivor n=45 | Survivor n=28 | p value | OR(95%CI)3 | |
| Gender, n (%) | ||||
| Male | 27(60%) | 19(68%) | 0.33 | |
| Female | 18(40%) | 9(32%) | ||
| Age, n (%) | ||||
| < 65> | 9(20%) | 21(75%) | 0.0001 | 4.3(2.0-8.8) |
| ≥ 65 year | 36(80%) | 7(25%) | ||
| Charlson comorbidity index, n (%) | ||||
| ≤3 | 16(36%) | 22(78%) | 0.001 | 3.3(1.5-7.3) |
| >3 | 29(64%) | 6(22%) | ||
| Treatment types, n (%) | ||||
| Convalescent plasma | 16(36%) | 6(22%) | 0.15 | |
| Blood product | 17(38%) | 3(10%) | 0.01 | 3.1(1.0-9.2) |
| Steroids | 28(64%) | 16(58%) | 0.42 | |
| Tocilizumab | 20(44%) | 16(42%) | 0.54 | |
| Nosocomial infection, n (%) | 33(74%) | 2(7%) | 0.0001 | 11.9(3.0-46.8) |
| DIC1 score, n (%) | ||||
| >5 | 15(34%) | 2(7%) | 0.008 | 3.9(1.0-14.9) |
| ≤5 | 30(66%) | 26(93%) | ||
| Thromboembolic events, n (%) | 6(14%) | 0(0%) | 0.07 | |
| Length of stay in ICU2 (days), n (%) | ||||
| >7 | 40(91%) | 12(A) | 0.0001 | 3.5(2.0-6.1) |
| ≤7 | 4(9%) | 17(Y) |
Table 1. Demographic data and risk factors for mortality in COVID-19 patients 1Disseminated intravascular coagulation (DIC), 2 Intensive care unit (ICU), 3Odds Ratio (OR), Confidence interval (CI).
Changes in Extended Inflammatory and Coagulation Parameters During 28 days
The median NLR level was significantly higher in nonsurvivors than in survivors during the first four weeks of follow-up (p<0>
NEUT-GI levels than survivors (p<0>0.05) (Table 2).
Table 2: Changes in extended inflammatory parameters and soluble fibrin monomer complexes during the first 28 days of intensive care monitoring.
1 Neutrophil-to-lymphocyte ratio, 2 Immature granulocyte-to-lymphocyte ratio, 3 Neutrophil reactivity index [FI], 4 Neutrophil granularity index [GI]
5 Antibody synthesizing lymphocytes count, 6 Antibody synthesizing lymphocytes as % of lymphocytes
7 Reactive lymphocytes count, 8Reactive lymphocytes as % of lymphocytes 9Soluble fibrin monomer complex.
Risk Factors
The proportion of older patients (age ≥65 years) among non-survivors (80%) was significantly higher than in survivors (25%), with a 4.3-fold increased risk (OR 4.3; 95%CI 2.0-8.8). Patients with Charlson morbidity score >3 had a 3.3-fold (OR 3.3; 95%CI 1.5-7.3) higher probability of death (64%) than survivors (22%). Patients who received blood products had a 3.1-fold (OR 3.1; 95%CI 1.0-9.2) increased risk of death (38%) than those who survived (10%). Patients with nosocomial infection had an 11.9-fold (OR 11.9; 95%CI 3.0-46.8) increased risk of death (74%) than those who survived (7%). Patients who had a DIC score >5 had a 3.9-fold (OR 3.9; 95%CI 1.0-14.9) increased risk of death (34%) compared to those who survived (7%). Patients who had a longer ICU stay >7 days had a 3.5-fold increased risk (OR 3.5; 95%CI 2.0-6.1) of death (91%) compared to those who survived (41%) (Table 2).
ROC Analysis and Calculation of Threshold Values
In ROC analysis, NLR (AUC: 0.73) and SFMC (AUC: 0.92) had significantly higher AUC values than other parameters. For predicting mortality, NLR had a sensitivity of 79.2% and a specificity of 65.2% with a threshold value of 6, whereas SFMC had a sensitivity of 94.2% and a specificity of 71.2% with a threshold value of 6.5 (Table 3) (Figure 1).
| NLR1 | SFMC2 | |
| AUC3 | 0.73 | 0.92 |
| 95%CI4 | 0.61-0.85 | 0.84-1.00 |
| P value | 0.001 | 0.0001 |
| Cut-off value | 6 | 6.5 |
| Sensitivity (%) | 79.2 | 94.2 |
| 95%CI | 64.5-89.3 | 80.8-99.3 |
| Specificity (%) | 65.2 | 71.2 |
| 95%CI | 42.8-78.4 | 54.1-84.5 |
| Diagnostic value (%) | 72.2 | 82.2 |
| 95%CI | 60.8-81.3 | 71.4-90.1 |
Table 3: ROC analysis for prognostic evaluation in COVID-19 patients to predict mortality.
1 Neutrophil-to-lymphocyte ratio (NLR), 2Soluble fibrin monomer complex (SFMC), 3Area under the curve (AUC), 4Confidence interval (CI).
The SARS-CoV-2 virus enters the body via endothelial ACE-2 receptors, causing endothelial damage, and microvascular inflammation. This endothelial disruption activates both the immune and coagulation systems simultaneously, contributing to severe clinical consequences such as severe acute respiratory distress syndrome and multi-organ dysfunction.22,23 Thus, we used research parameters capable of revealing early changes in the leukocyte series and SFMC measurements with the potential to provide early-stage information about coagulation activation. In this cross-sectional study, we examined the risk factors for COVID-19 infection, as well as the role of new extended inflammatory measures and SFMC in ICU patients. Our primary findings are as follows: i- In COVID-19 patients, risk factors for mortality include older age, comorbidities, blood product use, nosocomial infection, a high DIC score, and a longer ICU stay. ii- Elevated NLR, IGLR, NEUT-RI, NEUT-GI, D-dimer, and SFMC in the first two weeks of COVID-19 infection, followed by increasing NLR, D-dimer, RE-LYPMH, and AS-LYMPH in the next two weeks, may play an important role in thromboinflammation during COVID-19 infection. iii- The optimal cut-off values for NLR and SFMC in predicting mortality were 6 and 6.5, respectively. All of these findings suggest that the new extended inflammatory and coagulation parameters, including NLR and SFMC, could be useful for predicting COVID-19-related mortality.
Few studies focusing on the prognostic effect of extended inflammatory parameters in COVID-19 infection have been reported.15-17,24 Linssen and colleagues showed that they developed a prognostic score based on leukocyte data collected from noncritical (NC) and critical-fatal (CF) patient groups throughout a 14-day monitoring period.15 In that study, analysis of the leukocyte series revealed that the CF group had prolonged lymphopenia and high neutrophil counts, as well as elevations in NEUT-RI, IG, and IGLR levels throughout the course of COVID-19 infection. Similarly, we found a significant increase in IGLR and NLR ratios in the non-survivor patient group during the first two weeks of follow-up. This elevation was followed by increases in NEUT-RI and NEUT-GI levels in the second week. Our findings about the elevation in neutrophil precursors during the early stages of infection caused by the SARS-CoV-2 virus are consistent with Linssen and colleagues' 14-day follow-up study, and our data are also supported by previous sepsis studies that have shown increases in neutrophil precursors before the rise in neutrophil counts.7,15,25 Furthermore, we found that, while the increase in NLR continued during the third and fourth weeks of testing, the elevations in IG, NEUT-RI, and NEUT-GI did not. At this point, the AS-LYMPH count and percentage were significantly higher in our patients' survivors during the third week, whereas Linssen and colleagues found that the rate of AS-LYMPH was significantly higher in both (CF and NC) groups compared to baseline values during the second week of hospitalization.15 Similarly, Yip and colleagues found that, despite a gradual decrease in lymphocyte count, AS-LYMPH and RE-LYMH counts increased slowly in the critically ill group, with the most apparent change occurring on the 15th and 16th days.16 Another study by Martens and colleagues found that, while total lymphocyte count decreased in the group developing cytokine storms compared to the non-developing group, lymphocyte subgroups increased (AS-LYMPH, high fluorescence lymphocyte count, RE-LYMPH).24 The increase in AS-LYMP levels as a lymphocyte subgroup was associated with the seroconversion observed in the second week of the disease in those studies.15,16,24 As reported in another study, once antibody production begins, immunopathological events increase, and disease severity worsens.26 In our study, we examined weekly new extended CBC measures rather than daily ones and found a higher AS-LYMPH level at the beginning of the third week, which might indicate an emphasis on findings related to seroconversion. All of these findings may be linked to the adaptive immune system's increased disease severity.
Few studies revealed that mature and immature neutrophil counts increased at the start of the COVID-19 infection, and that increased AS-LYMPH and RE-LYMPH indicated an adaptive immune response that exacerbated disease severity in the second or third week of COVID-19 infection.15-17,24 On the other hand, NLR has been one of the most researched COVID-19 biomarkers.17,27,28 Kilercik and colleagues examined CBC values in non-critical and critical patients according to survival status.17 They found a decrease in monocyte and lymphocyte percentages, as well as the monocyte-to-neutrophil ratio (MNR), and an increase in neutrophil percentage and NLR as disease severity increased. They also demonstrated that MNR and NLR were the most reliable time-related parameters for predicting outcomes during 30 days.17 Similarly, in our investigation, NLR was the only parameter that remained significantly elevated over the 4-week follow-up period. Furthermore, two extensive meta-analyses of NLR in COVID-19 revealed its potential to predict disease severity and mortality.27,28 However, the predictive NLR threshold value is still debatable. Li and colleagues found an NLR cut-off value of 6.5 with an AUC of 0.92 (95% CI 0.89-0.94) in one of these meta-analyses.27 Another investigation on ICU patients, conducted by Regolo et al., identified an NLR cut-off value of>11.38 (AUC: 0.771, sensitivity 77.5%, specificity 65.9%).29 Using ROC analysis, we identified an NLR> 6 cut-off value with an AUC of 0.73, sensitivity of 79.2%, and specificity of 65.2%. We believe that the prolonged increase in NLR values over the 4-week follow-up period could be attributed to COVID-19-induced inflammation and secondary risk factors such as older age, comorbidities, and nosocomial infections, particularly as the prolonged length of ICU stay may have exacerbated the clinical progression of COVID-19 infection.
Unlike in previous research, SFMC was included in the analysis as a predictive marker in our investigation, along with extended inflammatory parameters. Hypercoagulability is the most common coagulation state in COVID-19 disease, which is caused by excessive inflammation and poor fibrinolysis, and patients are at risk of thromboembolic events.30 It is associated with a poor prognosis.30,31 D-dimer levels were the most often used coagulation parameter during the pandemic period.12 Many studies focused on COVID-19-associated coagulopathy in terms of mortality and critical illness prediction associated with D-dimer levels.32,33 Reduced fibrinolytic capability (fibrinolysis shutdown) was found in one of them, where COVID-associated coagulopathy was studied using thromboelastometry, and paradoxically, elevated D-dimer levels were observed.32 Another study suggested that high D-dimer levels could be caused by intra-alveolar fibrin deposits in the lungs.33 D-dimer levels were observed to be increased in the non-survivor patient group in our study and remained elevated during the 3-week follow-up period. Furthermore, because of difficulties in determining the D-dimer cut-off value and issues with inter-laboratory variability in D-dimer measurements, the development of alternative methods, such as fibrin monomer (FM), appears necessary for describing COVID-19-related coagulation disorders and outcomes.12,13 Severe coagulopathy and cases of DIC have been observed to be more common in severe disease and non-survivor patient groups during the course of COVID-19.34 Consistent with this, a DIC score greater than 5 was revealed as a major risk factor related to higher mortality in our study. The increase in D-dimer, a fibrin degradation product, shows the formation of stable clots by Factor XIII and the onset of fibrinolysis.35 Cross-linked fibrin protofibrils form before Factor XIII stabilization.36 Thrombin cleaves fibrinopeptides A and B from fibrinogen molecules, exposing active binding sites. Fibrin monomer is a modified version of fibrinogen. These monomers bind to other FMs or fibrinogen and circulate in a soluble form. These are known as soluble fibrin monomer complexes.36 Elevated SFMC levels indicate that the coagulation pathway has been activated and the clotting process has begun. This early information on the coagulation process presented by SFMCs is thought to guide optimal treatment.37 High D-dimer levels in COVID-19 have been linked to the extent of lung damage outside of the coagulation system, and this has been explained by the breakdown of extravascular fibrin deposits.38 Fibrin monomers, on the other hand, are restricted to the intravascular area. A few studies have been carried out to examine the prognostic value of FM in COVID-19.12,39,40 The majority of them demonstrated that SFMC levels were not superior to D-dimer levels in predicting multiple thrombotic events on admission. The largest study in this field, however, was conducted by Smadja et al., who analyzed FM levels in 246 patients who were observed in the ICU and general hospital for 9 days.14 They showed that SFMC levels in patients admitted promptly to the ICU began to rise dramatically on day 3 and remained elevated for at least 9 days. They established the FM detection limit at 7 g/mL. These findings are consistent with our findings, which indicated a similar cut-off value of 6.5 g/mL for FM with a sensitivity of 94.2% (95% CI 80.8-99.3) and specificity of 71.2% (95% CI 51.1-84.5) in predicting mortality. Finally, similar to our study, SFMC levels were significantly higher in non-survivor patients compared to survivors in the first week of ICU follow-up. All of these findings suggested that monitoring FM levels during the follow-up period, rather than just at the time of admission, could be valuable for predicting death.
Our study's main limitations are the small number of patients and the lack of a healthy control group. One of our study's advantages is its potential to guide future research on COVID-19-like viruses that influence the hemostatic system. Future research will require a large patient group as well as a healthy control group.
Finally, increasing NEUT-RI, NEUT-GI, NLR, and IGLR during the first two weeks of COVID-19 infection may support acute inflammation, whereas increasing RE-LYPMH and AS-LYMPH during the next two weeks may indicate COVID-19 seroconversion. Elevated D-dimer and SFMC levels in the first week of COVID-19 infection could support the prethrombotic process, and significantly higher D-dimer levels in the next three weeks may assist the thrombotic process. Our findings suggest that elevated NLR and SFMC cut-off values in the first week should alert clinicians to the possibility of life-threatening COVID-19 complications and highlight the importance of prophylactic treatments such as broad-spectrum antibiotics or anticoagulant therapy.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.
